Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the best cancer stocks on our list.

TheFly reported on April 23 that Goldman Sachs lowered its rating on RDY from Neutral to Sell and reduced the price target from INR 1,225 to INR 1,075, citing concerns that the company’s generic Ozempic prospects in Canada may be weaker and more short-term than previously expected due to rising competition. The firm also noted that RDY’s pipeline for high-value drugs remains limited.

Moreover, on April 29, Dr. Reddy’s Laboratories Limited (NYSE:RDY) announced that it had secured regulatory clearance from Health Canada for its generic semaglutide injection, marking a significant step for the company in the Canadian market. The approval makes RDY’s the first drugmaker to obtain authorization to market a generic version of semaglutide in Canada before Health Canada’s expected review timeline.

Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

The authorization includes both the 2 mg/pen and 4 mg/pen versions of the treatment. The company stated that commercial launch activities are already in progress, positioning it to expand access to the medication for patients across Canada. The development also strengthens RDY’s presence in the growing market for diabetes and weight management treatments.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is a global pharmaceutical company based in Hyderabad. Founded in 1984, it develops and manufactures generics, APIs, biosimilars, and branded medicines, with a strong presence in oncology, cardiovascular care, and emerging markets.

While we acknowledge the risk and potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RDY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now  and 9 Most Undervalued Healthcare Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.